Compare DRUG & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRUG | BRBI |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.8M | 365.4M |
| IPO Year | N/A | N/A |
| Metric | DRUG | BRBI |
|---|---|---|
| Price | $83.06 | $13.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $83.00 | N/A |
| AVG Volume (30 Days) | ★ 159.4K | 21.7K |
| Earning Date | 12-29-2025 | 02-10-2026 |
| Dividend Yield | N/A | ★ 5.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.31 |
| P/E Ratio | ★ N/A | $11.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.18 | $12.15 |
| 52 Week High | $97.75 | $67.01 |
| Indicator | DRUG | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | N/A |
| Support Level | $77.80 | N/A |
| Resistance Level | $97.75 | N/A |
| Average True Range (ATR) | 8.78 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 48.68 | 0.00 |
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.